Our first main finding of this meta‐analysis was that all tau PET tracers assessed demonstrate trends towards higher binding in AP patients (i.e., PSP, and CBD) when compared to HC and PD. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.